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Background: Chronic spontaneous urticaria (CSU) formerly known as chronic idiopathic urticaria (CIU) is a severe
and distressing skin condition that remains uncontrolled in approximately one half of patients, despite the use of
licensed, recommended doses of modern, second-generation H1-antihistamines. So far, the humanistic, societal and
economic burden of CSU/CIU has not been well quantified. Therefore it is important to broaden our understanding
of how CSU/CIU impacts patients, society, and healthcare systems, by determining the disease burden of CSU/CIU and
the associated unmet need; as well as to further guide the use of new treatments in an efficient and cost-effective
manner.
Methods: ASSURE-CSU is an observational, multicenter study being conducted in the UK, Germany, Canada, France,
Italy, Spain, and The Netherlands. The study comprises a retrospective medical chart review in conjunction with patient
surveys (including validated tools for assessment of disease impact) and an 8-day patient diary. The primary objectives
of the study are to describe patient demographics, medical history, treatments, and healthcare resource utilization
based on medical-record data and to assess the impact of disease, healthcare resource utilization, work days missed,
and productivity loss based on patient-reported data. Approximately 700 patients (aged ≥18 years) will be enrolled
who have CSU/CIU despite currently receiving treatment, and have had persistent symptoms for at least 12 months.
Data will be collected retrospectively for the 12 months (±1 month) prior to enrolment wherever possible, and
prospectively for the week following enrolment.
Discussion: ASSURE-CSU will be the first study to examine the economic and humanistic burden of disease in patients
diagnosed with CSU/CIU who are symptomatic despite treatment. By combining retrospective evaluation of medical
records with prospective patient surveys and 8-day diaries, across seven different countries, the ASSURE-CSU study will
contribute to a better understanding and acknowledgement of the burden of disease in patients with symptomatic
chronic spontaneous urticaria.
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Urticaria is characterized by the sudden appearance of
hives, angioedema or both [1]. Chronic spontaneous
urticaria (CSU), formerly known as chronic idiopathic
urticaria (CIU) is defined by the spontaneous develop-
ment of itchy hives and/or angioedema that reoccur
for at least 6 weeks due to known or unknown causes
[1]. CSU/CIU is thought to affect 0.5–1 % of the glo-
bal population at any given time, with CSU/CIU ac-
counting for approximately two-thirds of all cases of
chronic urticaria (CU) [2]. It has been estimated that
33–67 % of patients with CSU/CIU have both hives
and angioedema, with 29–65 % having hives alone
and 1–13 % angioedema alone [2]. Although the clin-
ical features and pathogenesis of CSU/CIU have been
well studied over the past decade [3], the humanistic
and economic burden of CSU/CIU have not been elu-
cidated in detail, specifically, in patients with an inad-
equate response to first-line therapies.
However, generally across all patient types, CSU/CIU
can have a considerable burden on patients, healthcare
systems and society. Moreover, the current standard of
care, H1-antihistamines at licensed doses, is only effect-
ive at resolving symptoms in less than 50 % of patients
with CSU/CIU. Further increases in dose of H1-antihis-
tamines does improve treatment response, but every
third or fourth patient is thought to remain refractory
(symptomatic despite treatment) [2], and may therefore
have a higher burden of disease when compared to non-
refractory patients. The burden of disease is also particu-
larly high in patients with CSU/CIU and associated an-
gioedema, which, when compared to hives alone, can
increase disease severity and duration [2]. In addition to
the impact of the physical signs and symptoms, CSU/
CIU can also have a profound impact on the lives of pa-
tients due to factors such as sleep disruption, anxiety,
embarrassment, depression and social isolation [2, 4–7].
Many aspects of daily activities (e.g., choice of clothes or
going to the shops [8]) are also negatively impacted in
patients with CSU/CIU [2]; and for those patients
who are employed, impaired work performance or
even absence from work are common [2, 9]. There is
also a need to ensure timely and appropriate referral
of patients with CSU/CIU to specialists in order to
reduce delays in their diagnosis and the implementa-
tion of effective pharmacological management. This is
especially true for those patients who are symptom-
atic despite on-going treatment with current standard
of care. In many cases this need is not met, with pa-
tients seeing an average of more than two physicians
before being referred to a specialist [10]. Reducing the
burden associated with CSU/CIU therefore requires a
broader understanding of the impact of these unmet
needs of patients [2].The guidelines recommend a stepwise approach in
the management of CSU, beginning with licensed
doses of H1-antihistamines [1]. However, many pa-
tients remain uncontrolled and in these situations,
current guidelines recommend increasing the dose by
up to four-fold [1]. In patients non-responsive to higher
doses of H1-antihistamines, guidelines recommend the
addition of a third-line treatment option of omalizumab,
ciclosporin or montelukast [1]. Among these third-line
options, only omalizumab is currently approved as add-on
therapy for the treatment of CSU/CIU in adult and ado-
lescent (≥12 years) patients showing an inadequate re-
sponse to H1-antihistamine treatment.
Few studies have specifically evaluated the economic
impact of CSU/CIU. In 2005, DeLong and colleagues
estimated the total annual cost in the US as being
$2047 per patient, with indirect costs accounting for
15.7 % ($322) [9]. Another study analyzing 2002 data
estimated the total annual cost in France as being
€2128 per patient, with productivity costs accounting
for 92.2 % (€1962) [11]. Studies based on insurance
claims cannot assess clinical aspects and patient per-
spectives because they lack recorded clinical data; it
is also possible that the lack of specific International
Classification of Diseases (ICD) code for CSU/CIU
[12], may have resulted in an underestimated number
of affected patients. As such, the true economic cost
of CSU/CIU needs to include both direct costs, such
as medication and costs of treatment, as well as indir-
ect costs related to lack of productivity and absence
from work.
Importantly, there are no studies which specifically evalu-
ate the burden of disease in patients who are non-
responsive to standard-of care (H1-antihistamines at li-
censed doses). The objective of ASSURE-CSU is to identify
and quantify the humanistic, societal and economic bur-
den of disease in patients with inadequately controlled
CSU/CIU, with a focus on patients whose disease persists
for ≥12 months. This study will evaluate health-related
quality-of-life (HRQoL) using patient-reported outcomes
(PROs), healthcare resource utilization, absence from work
and productivity loss among patients with CSU who are
currently symptomatic despite treatment. This study, col-
lecting real-world data in this patient population, will con-
tribute to a better understanding of the impact of CSU/
CIU and its associated unmet need.
Methods/design
Study design and participants
ASSURE-CSU is an observational, multinational, mul-
ticenter study being conducted in seven countries
(UK, Germany, Canada, France, Italy, Spain and The
Netherlands). The study has two components: a retro-
spective medical chart review including patient medical-
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eral validated PROs (Fig. 1). These measures will assess
disease and dermatological quality of life (QoL), general
health status, symptoms and also the impact of CSU/CIU
on work and activities. Planned enrolment is approxi-
mately 700 CSU/CIU patients (approximately 100 patients
from an average of 10 centers in each participating coun-
try) who are at least 18 years of age, are symptomatic des-
pite current treatment, and have symptoms that have
persisted for at least 12 months. Inclusion and exclusion
criteria are detailed in Table 1.
Objectives
The primary objectives of the study are to describe pa-
tient demographic characteristics, medical history, treat-
ments and healthcare resource utilization based on
medical record data; as well as impact of disease, health-
care resource utilization, work days missed and pro-
ductivity loss based on patient-reported data (Table 2).Fig. 1 Study protocol. CSU chronic spontaneous urticaria; PRO patient-repo
CU-Q2oL Chronic Urticaria Quality-of-Life Questionnaire; DLQI Dermatology
Urticaria Activity Score; WPAI-SHP Work Productivity and Activity ImpairmenSecondary objectives are to collect the following infor-
mation from medical records and patient-reported data:
number of patients receiving guideline recommended
treatments (EAACI/GA2LEN/EDF/WAO [1]); diagnostic
code or terminology used to identify CSU/CIU, as re-
corded in the medical records (e.g., chronic idiopathic/
chronic ordinary versus chronic spontaneous urticaria);
treatment response as available in the medical record;
disease severity and symptoms linked to medical re-
sources; loss of productivity and impact on patients’
HRQoL.
Data collection
Clinical staff in tertiary care review patient medical re-
cords and capture demographic, clinical, and healthcare
resource data, to be extracted via a web-based electronic
data capture application. Retrospective data are collected
for the previous 12 months (±1 month) prior to study
enrolment. The following data are collected: patientrted outcome; AE-QoL Angioedema Quality-of-Life Questionnaire;
Life Quality Index; EQ-5D-3L three-level EuroQoL-5D; UAS7 Weekly
t – Specific Health Problems
Table 1 Patient selection criteria in the ASSURE-CSU study
Inclusion criteria Exclusion criteria
• Clinician-confirmed diagnosis of CSU/CIU, defined as occurrence of
spontaneous hives and/or angioedema for at least 6 weeks without an
obvious cause
• Symptoms resolved within 12 months of diagnosis
• Symptomatic for more than 12 months at least 3 days per week and
currently symptomatic despite treatment
• Determined to be in remission/resolved, defined as more than 6 months
untreated and without symptoms
• Under care of the participating site/physician for at least 12 months or
the participating site/physician has documentation of the patient’s
relevant medical information (e.g., referral letters) for the 12 months
prior to enrolment
• Urticaria is predominantly of the inducible form (i.e., physical, cholinergic);
however, patients with comorbid inducible urticaria may be included in the
study provided that it is of secondary importance to CSU/CIU
• Received at least one treatment course with an H1-antihistamine
(licensed dose)
• Participated in a CSU/CIU interventional study or clinical trial during the
data collection period
• Able to provide informed consent • Unable to provide informed consent
• Willing and able to complete the surveys • Not able and not willing to complete the surveys
• Aged 18 years or older at the time of study enrolment
CSU chronic spontaneous urticaria




• Medical record abstraction form
• Patient survey
Unit costs
Country-specific unit cost estimates will be applied where available,
using standard national sources, e.g.,
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line medical history including co-morbidities, duration
and severity of CSU/CIU; treatments received for CSU/
CIU including duration and treatment response; health-
care resource utilization related to CSU/CIU, including
the type and specialty of healthcare professional visited
and frequency of visits and the number of emergency
room visits. Further details of the estimation of direct
and indirect costs are summarized in Table 3.
Patient-completed surveys and 8-day diaries collect
information from all eligible patients. The cross-
sectional surveys capture information on healthcare
resource utilization related to CSU/CIU and specific-
ally angioedema, if applicable. This includes the num-
ber of patient-reported medical visits (not recorded in
medical record charts), as well as out-of-pocket costsTable 2 Primary assessments of the ASSURE-CSU study
Medical record data Patient-reported data




• AE-QoL (in patients
with angioedema)
Baseline medical history Angioedema history and characterization
Treatment received for
CSU/CIU
Healthcare resource utilization (other than
that recorded in charts, use of alternative
medications and out-of-pocket expenses)
Duration of treatments Disease activity (UAS7)
Total healthcare resource
utilization
Work days and productivity loss
(WPAI-SHP)
EQ-5D-3L three-level EuroQoL-5D, DLQI Dermatology Life Quality Index,
CU-Q2oL Chronic Urticaria Quality-of-Life Questionnaire, AE-QoL Angioedema
Quality-of-Life Questionnaire, CSU chronic spontaneous urticaria, UAS7 Weekly
Urticaria Activity Score, WPAI-SHP Work Productivity and Activity
Impairment – Specific Health Problemsincluding transportation/parking costs. Impact of dis-
ease will be assessed using four validated PROs: the
Dermatology Life Quality Index (DLQI), Chronic Urticaria
Quality-of-Life Questionnaire (CU-Q2oL), three-level
EuroQoL-5D (EQ-5D-3L) and, in patients with angio-
edema, the Angioedema Quality-of-Life Questionnaire• UK National Health Service Reference Costs
• German Einheitlicher Bewertungsmaßstab (Uniform Rating Scale)
• National drug formularies
• National average wage statistics
Direct health care costs (all CSU-related)
• Physician visits, including private practice visits
• Emergency room visits
• Hospitalizations




Indirect costs (employed patients; CSU-related)
• Lost productivity due to sick leave and early retirement
(analyzed using the friction cost approach)
• Reduced productivity due to reduced performance at work
(presenteeism)
CSU chronic spontaneous urticaria
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with dermatological disorders and is not specific to
CSU/CIU, but has been used previously across a num-
ber of dermatologic diseases (including CSU/CIU) and
measures overall impact on HRQoL in such dermato-
logical conditions [13, 14]. It has a seven day recall
period and scores from 0 to 30 with higher score mean-
ing higher impact and lower QoL.
The CU-Q2oL, which measures various aspects of
chronic urticaria specific QoL impairment [15], has a two
week recall period and a score from 0 to 100, with higher
score indicating higher QoL impairment.
The EQ-5D-3L is a generic tool that is used to meas-
ure health status in a wide variety of diseases [16, 17]. It
assesses the impact of disease in that day and allows the
calculation of a utility score ranging from 0 (death) to 1
(perfect health).
The AE-QoL assesses the impact of angioedema on
patient QoL [18]. In addition the angioedema survey al-
lows a description of angioedema episodes with their fre-
quency, localization, symptoms and duration.
The patient diary collects seven days of information
on disease activity using the Urticaria Activity Score
(UAS) and on day 8, work absence and productivity in-
formation using the Work Productivity and Activity
Impairment-Specific Health Problems (WPAI-SHP)
questionnaire. The UAS is a validated diary-type tool
that daily assesses disease activity through the severity of
symptoms (hives and itch) [19]. It is usually scored over
a period of seven days to give the weekly UAS score
(UAS7) ranging from 0 to 42, with higher scores indicat-
ing greater disease severity [20]. The validity and repro-
ducibility of the WPAI-SHP questionnaires are well
established in a number of specific diseases (including
the dermatological condition chronic hand dermatitis)
[21]. This questionnaire captures absence from work (ab-
senteeism), reduced productivity while at work (presentee-
ism), overall activity impairment and has a recall period of
seven days.
Data analyses
All study results will be summarized descriptively for
each country (apart from direct and indirect costs which
will estimated for each country using validated local
sources) and for the pooled population across all coun-
tries. This includes a tabular display of mean values, me-
dians, ranges, standard deviations for continuous variables
of interest and frequency distributions for categorical vari-
ables. Results will be stratified by disease severity as mea-
sured by the UAS7 score.
For data on healthcare resource utilization, costs will
be calculated for items by estimated unit costs for each
resource per country. All cost data will be inflated to the
most current cost year (2013/4) and adjusted to thecurrency value for each country where appropriate. In-
direct costs will be estimated using the WPAI results for
employed patients only, which uses an algorithm rele-
vant for each country, based on average number of
weekly hours worked and the hourly country-specific
wage. The total indirect cost, presented also as overall
work impairment cost, incorporates both absenteeism
and presenteeism related costs.
In addition to descriptive statistical summaries of study
results, where appropriate, multivariate analyses may be
conducted to assess the differences in resource utilization
and cost outcomes between levels of disease severity.
Discussion
Currently available literature points to a significant hu-
manistic and economic burden for patients with CSU/
CIU as well as considerable demands on healthcare re-
sources [2, 5–7, 9]. As up to 50 % of patients do not
fully respond to currently recommended first-line ther-
apy (H1-antihistamines at licensed doses) [2], further
analysis is required to fully understand the disease burden
in this particular subgroup of patients. ASSURE-CSU is
the first study to address this unmet need. Its design will
allow collection of medical resource utilization data and
patient perspectives on a disease with an unrecognized
burden. A better understanding of patient journey, time
between onset, diagnosis and management will hopefully
result in an optimized approach to patient management.
ASSURE-CSU does have some limitations which can
be listed. Firstly, the study is only for patients with CSU/
CIU who are symptomatic despite treatment with current
standard of care (H1-antihistamines at licensed doses). Re-
sults are obtained from large treatment centers within
each participating country, as such, information on pa-
tients who are not currently being treated or that are be-
ing treated by an office-based dermatologist/allergist will
not be captured. Furthermore, it should be noted that pa-
tients may be symptomatic due to additional factors such
as poor treatment compliance, under-treatment or treat-
ment which has not been optimized for the patient.
The quantity and quality of the data obtained by med-
ical record abstraction will be dependent on availability
and accuracy of the data in the physicians’ records (e.g.,
duration of treatment, type of therapies or the relative
success of previous treatments). As only 12 months of
retrospective data are collected, a full picture of the pa-
tient since diagnosis is not obtained. A record of patient
symptoms is collected prospectively for seven days using
the UAS but this will only provide a snapshot of disease
severity related to the UAS7 score of the representative
week; this is particularly important to note, as disease
severity can vary, and symptoms resolve over time.
Finally, although the ASSURE-CSU study has a broad
number of objectives, because of its cross-sectional
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natural disease history, natural remission rates, prevalence
of CU or CSU/CIU, proportion of refractory patients, or
proportion of responders to each therapy (within a coun-
try or globally). Neither will information on those patients
who have H1-antihistamine-responsive CSU be collected,
as they are outside of the focus of this analysis.
As far as we are aware, ASSURE-CSU will be the first
international multicenter study to examine the economic
and humanistic burden of disease on patients who are
symptomatic despite current recommended first-line
therapy. By using a combination of retrospective (patient
medical-record abstraction) and prospective (patient sur-
veys and 7-day diary) analysis across seven different
countries, the ASSURE-CSU study can increase the un-
derstanding of the impact of CSU/CIU on patients and
the associated costs. ASSURE-CSU will inform us of the
patient journey, the potential success of management for
refractory CSU/CIU and also possible ways to improve
the perspectives that different stakeholders have on this
disease. The study has been completed in five countries
and data collection in the remaining countries is planned
to be completed by the end of April 2015.
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